Alan Ezekowitz Sells 18,000 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Alan Ezekowitz sold 18,000 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the sale, the director directly owned 10,927 shares in the company, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Fulcrum Therapeutics Stock Down 1.9%

Shares of NASDAQ:FULC traded down $0.07 during midday trading on Tuesday, hitting $3.66. 2,421,701 shares of the stock traded hands, compared to its average volume of 1,644,518. The business’s 50 day moving average is $5.66 and its two-hundred day moving average is $8.25. The stock has a market capitalization of $243.87 million, a PE ratio of -3.18 and a beta of 2.93. Fulcrum Therapeutics, Inc. has a one year low of $2.83 and a one year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. As a group, sell-side analysts forecast that Fulcrum Therapeutics, Inc. will post -0.67 earnings per share for the current year.

Analysts Set New Price Targets

FULC has been the subject of a number of recent analyst reports. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price for the company. in a report on Tuesday, June 2nd. Citigroup downgraded shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. Piper Sandler lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a report on Tuesday, June 2nd. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, JPMorgan Chase & Co. lowered shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $8.20.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Fulcrum Therapeutics in the fourth quarter worth $30,000. Quarry LP purchased a new position in Fulcrum Therapeutics during the third quarter valued at $35,000. Meeder Asset Management Inc. bought a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at $39,000. Summit Securities Group LLC bought a new stake in shares of Fulcrum Therapeutics during the 1st quarter valued at $53,000. Finally, Russell Investments Group Ltd. grew its position in shares of Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after buying an additional 9,092 shares during the period. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.